Biosimilars represent a disruptive new category of specialty drugs and there is significant speculation that oncology may uniquely adopt or accept them vs other therapeutic areas. Furthermore, biosimilars represent a vehicle and potential critical driver of value for the US market and beyond. Download the report for insight into the drivers and barriers of biosimilar adoption, ways that biosimilar manufacturers can differentiate, and top issues originators or next-generation product manufacturers should consider.

ZS Oncology Value Watchdog Report: Biosimilars in Therapeutic Oncology

Home / Insights / Publication

Christina Corridon